فريق إنت عربي
- US-Based XCath Raises $30 Million in Series C to Advance Neuro-Endovascular Surgical Robotics
- The funding will support remote robotic interventions for stroke treatment
XCath, a US company specializing in neuro-endovascular surgical robotics, has raised $30 million in a Series C funding round, bringing its total capital raised since inception to $92 million.
The round was led by UAE-based Crescent Enterprises.
The new funding will support XCath’s efforts to bring its technology to market and enable remote robotic interventions for stroke treatment.
Earlier, the company completed a robot-assisted procedure using its Iris system to treat patients with complex brain aneurysms.
The procedure was performed by Dr. Vitor Mendes Pereira at Panama Clinic, in collaboration with local principal investigator Dr. Anastasio Ameijeiras Sibauste, marking the second time a robotic system has been used in an intracranial neurovascular intervention.
Neeraj Agrawal, Executive Director of Crescent Enterprises, said:
“Our firm has a strong appetite for early-stage transformational companies. XCath’s technology will help address stroke and related conditions while reducing pressure on global healthcare systems.”
He added:
“XCath’s technology enables precise remote interventions. Strokes are among the most promising areas for robotics and remote procedures due to geographical challenges and the need for timely intervention. These solutions enhance surgical precision while integrating AI to support decision-making and ensure patient safety.”
About XCath
Founded in 2017 as a spinout from the University of Texas’ Microsurgical Robotics Laboratory, XCath is developing a clinical-grade endovascular robotic system.
